Chronic HD responds to bexarotene gel


Portland, OR - In a small study of bexarotene gel treatment for chronic severe hand dermatitis (HD), the medication achieved both speedy and surprising results. In a 55-patient, phase 1-2 open-label randomized clinical study of the gel, used alone and in combination with one of two steroids, 79 percent of patients on monotherapy achieved clinical improvement of at least 50 percent, and 39 percent reached at least 90 percent clearance.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.